Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
If approved, the nasal spray formulation would provide an additional ... A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback